focus -WSS

focus

author：hotspot 2025-09-27 06:03:24 - browse：35

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： How one medical school became remarkably diverse
Next article： Does Paxlovid work in people vaccinated against Covid

WSS

Medicare Advantage coverage denials need scrutiny, senators say

UCB departs biotech trade group BIO

Boston Scientific acquires urology company Axonics for $3.7 billion

Antibiotic resistance and the global rise in human conflict

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

U.K. sequencing study surfaces new findings about tumor DNA

hotspot

focus

knowledge

In Memoriam: Notable people who died in 2023

3 medical device trends to watch in 2024

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

3 medical device trends to watch in 2024

Cancer drug shortages should be causing more outrage

Medicare Advantage overpayments discussion gets experts fired up

Affirmative action in medical school literally saved lives

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Allen Institute goes after foundational questions, CEO Costa says

focus

Allen Institute goes after foundational questions, CEO Costa says

Study suggests new cause of Down syndrome: cells linked to aging

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

At JPM 2024, hospital systems pitch financial strength to investors

American taxpayers paid $1.8 trillion in health care costs in 2022

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

explore

entertainment

entertainment

hotspot